Ms Chong joined the group in September 2015 from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 23 years' experience in leading clinical and department development in oncology. In November 2016, Ms Chong was promoted as Imugene's CEO and joined the board as Managing Director in March 2018. Her other current directorships are Chimeric Therapeutics (ASX: CHM), since 28 August 2020 Cure Brain Cancer Foundation (non-profit organisation), since April 2020

Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Other current directorships held by him are at Radiopharm Theranostics Limited, since 11 February 2021 Chimeric Therapeutics Limited (ASX: CHM), since 2 February 2020 Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), since December 2020 SUDA Pharmaceuticals Ltd (ASX: SUD), since 15 May 2019

Mr Walker has experience across the biotechnology and life sciences industry. His experience includes operational and leadership positions in biotechnology firms, a strong capital markets track record from executing nearly 60 international and domestic corporate transactions, both as principal and advisor, and a detailed scientific understanding gained from a technical background in pharmacology. Mr Walker was previously Chief Executive Officer and Chief Financial Officer of Alchemia Limited (ASX: ACL) and Managing Director of Imugene.

Dr Hoos is the CEO of Scorpion Therapeutics. Formerly, he was the Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). At GSK he led technical and funding decisions in R&D as well as Discovery and Development in Oncology with focus on immunooncology, epigenetics, cell therapy, and synthetic lethality. Dr Hoos also serves as a member of the Board of Trustees of the Sabin Vaccine Institute (SVI), a global health organization, Director on the Board of TCR2, a cell therapy company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first checkpoint inhibitor in Immuno-Oncology. Before BMS, Dr Hoos was Senior Director of Clinical Development at Agenus Bio (former Antigenics). Other current directorships of his are at TCR2 Therapeutics Inc (NASDAQ: TCRR)

Dr Russell is a haematologist/oncologist and has over 25 years' experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships held by her are Chimeric Therapeutics Limited (ASX: CHM), since 28 August 2020 Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016 Former directorships in last 3 years held by her are Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), until March 2021 AMAG Pharma (NASDAQ: AMAG), until May 2019 Endocyte Pharmaceuticals (NASDAQ: ECYT), until December 2018

Dr Eckstein has more than 15 years' venture capital experience in the biopharmaceutical industry and 10 years' operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Other current directorships held by him are Aeovian Pharmaceuticals (USA, private) Samsara Therapeutics (UK, private) Cleara Biotech (The Netherlands, private) HAYA Therapeutics (Switzerland, private) BosWell (USA, private) Former directorships in last 3 years held by him are Gladius Pharmaceuticals (Canada, private) Decibel Therapeutics (NASDAQ:DBTX) Palleon Pharmaceuticals (USA, private) ZappRx (USA, private)

-

-

-

-

-

-